GPCR Crystallization via Stable Protein Insertion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for crystallizing G-protein coupled receptors (GPCRs) face challenges in achieving stable and functional crystal structures, particularly due to the difficulty in maintaining the receptor's native conformation and resistance to proteolysis, which hinders the determination of their atomic coordinates and understanding of their signaling mechanisms.
Innovation Solution
A fusion protein is created by incorporating a stable, folded protein insertion, such as lysozyme, between the TM5 and TM6 regions of the GPCR, which stabilizes the receptor and allows for crystallization using methods like bicelle or lipidic cubic phase crystallization, enabling the production of active, protease-resistant crystals with preserved functional properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional crystallization methods are used for GPCRs, then the receptor may be crystallized, but the crystal structure is unstable and lacks functional integrity due to proteolysis and conformational changes
Solution Approach 1:
A soluble protein partner (such as antibody fragments, T4 lysozyme, or other stable proteins) is introduced as an intermediary to form a fusion protein with the GPCR. This partner protein stabilizes the GPCR conformation, protects it from proteolysis, and facilitates crystallization while maintaining the receptor's functional integrity and active state.
2Measurement precision
If the GPCR is crystallized to determine atomic coordinates, then structural information is obtained, but the receptor loses its functional properties and active conformation
Solution Approach 1:
The GPCR is merged with a stable, crystallizable protein partner to form a fusion protein. This combination allows the GPCR to retain its functional properties and active conformation while the fusion partner provides structural stability for crystallization, enabling simultaneous achievement of high-resolution structural determination and functional integrity.
3Ease of manufacture
If the GPCR is exposed to proteases during crystallization, then purification is achieved, but the receptor is degraded and cannot maintain its native conformation
Solution Approach 1:
The soluble protein partner serves as a protective intermediary that shields the GPCR from proteolytic degradation. The fusion protein can be purified using standard protease treatment protocols, but the partner protein protects the GPCR core from degradation, maintaining its native conformation and functional properties throughout the purification and crystallization process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach allows for the successful crystallization of GPCRs in an active form, providing high-resolution structures and insights into ligand binding and receptor activation mechanisms, while maintaining the receptor's functional integrity and stability.
Implementation Method 1
a stable, folded protein insertion, e.g., the amino acid sequence of lysozyme... the stable folded protein insertion is a polypeptide than can fold autonomously in a variety of cellular expression hosts, and is resistant to chemical and thermal denaturation
Implementation Method 2
The fusion protein may be disposed on the plasma membrane of the cell... crystals comprising the above described fusion protein, folded into an active form... crystallizing the fusion protein to make crystals
Data Source
AI summary
Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR.